These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 31955626)

  • 61. Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E
    Yoshino K; Hosooka T; Shinohara M; Aoki C; Hosokawa Y; Imamori M; Ogawa W
    Biochem Biophys Res Commun; 2021 Jun; 557():62-68. PubMed ID: 33862461
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice.
    Iwamoto Y; Kimura T; Dan K; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nogami Y; Shirakiya Y; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Obes Metab; 2024 Jun; 26(6):2339-2348. PubMed ID: 38504118
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.
    Sakaeda T; Kobuchi S; Yoshioka R; Haruna M; Takahata N; Ito Y; Sugano A; Fukuzawa K; Hayase T; Hayakawa T; Nakayama H; Takaoka Y; Tohkin M
    Int J Med Sci; 2018; 15(9):937-943. PubMed ID: 30008607
    [No Abstract]   [Full Text] [Related]  

  • 64. Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin.
    Takahara M; Shiraiwa T; Matsuoka TA; Katakami N; Shimomura I
    Endocr J; 2015; 62(1):77-86. PubMed ID: 25328035
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
    J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.
    Alkabbani W; Gamble JM
    Drug Des Devel Ther; 2021; 15():3057-3069. PubMed ID: 34285473
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice.
    Yaginuma H; Banno R; Sun R; Taki K; Mizoguchi A; Kobayashi T; Sugiyama M; Tsunekawa T; Onoue T; Takagi H; Hagiwara D; Ito Y; Iwama S; Suga H; Arima H
    J Pharmacol Sci; 2021 Dec; 147(4):340-347. PubMed ID: 34663516
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats.
    Zou W; Zhang C; Gu X; Li X; Zhu H
    Drug Des Devel Ther; 2021; 15():2565-2576. PubMed ID: 34168429
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice.
    Kamezaki M; Kusaba T; Komaki K; Fushimura Y; Watanabe N; Ikeda K; Kitani T; Yamashita N; Uehara M; Kirita Y; Shiotsu Y; Sakai R; Fukuda T; Yamazaki M; Fukui M; Matoba S; Tamagaki K
    Sci Rep; 2018 Mar; 8(1):4029. PubMed ID: 29507299
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
    Shiba K; Tsuchiya K; Komiya C; Miyachi Y; Mori K; Shimazu N; Yamaguchi S; Ogasawara N; Katoh M; Itoh M; Suganami T; Ogawa Y
    Sci Rep; 2018 Feb; 8(1):2362. PubMed ID: 29402900
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
    Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
    Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Eur J Pharmacol; 2017 Aug; 809():163-171. PubMed ID: 28506912
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
    Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
    World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
    Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice.
    Miyazaki T; Shirakami Y; Kubota M; Ideta T; Kochi T; Sakai H; Tanaka T; Moriwaki H; Shimizu M
    Oncotarget; 2016 Mar; 7(9):10448-58. PubMed ID: 26871288
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
    Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
    [TBL] [Abstract][Full Text] [Related]  

  • 78. First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats.
    Takakura S; Takasu T
    Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):266-273. PubMed ID: 30485488
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis.
    Chun HJ; Kim ER; Lee M; Choi DH; Kim SH; Shin E; Kim JH; Cho JW; Han DH; Cha BS; Lee YH
    Metabolism; 2023 Aug; 145():155612. PubMed ID: 37277060
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
    Nagai Y; Ohta A; Sada Y; Kato H; Tanaka Y
    Expert Opin Pharmacother; 2017 Jan; 18(1):13-17. PubMed ID: 27841020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.